论文部分内容阅读
目的研究趋化因子受体CXCR7在甲状腺乳头状癌(PTC)组织中的表达,并探讨其表达与PTC临床病理特征的关系。方法采用免疫组织化学SP法检测79例PTC及其癌旁2 cm甲状腺正常组织以及33例良性甲状腺疾病组织中CXCR7的表达。结果在PTC癌组织中,CXCR7表达阳性率为65.8%(52/79),在甲状腺癌旁正常组织中CXCR7表达阳性率为0(0/79),在良性甲状腺疾病中CXCR7表达阳性率为30.3%(10/33)。PTC癌组织中CXCR7表达阳性率明显高于良性甲状腺疾病组织(P<0.05)及其癌旁甲状腺正常组织(P<0.05)。CXCR7阳性表达与PTC淋巴结转移有关(P<0.05)。结论 CXCR7可能参与了PTC的发生、发展及淋巴结转移。
Objective To investigate the expression of chemokine receptor CXCR7 in papillary thyroid carcinoma (PTC) and to explore the relationship between its expression and clinicopathological characteristics of PTC. Methods Immunohistochemical SP method was used to detect the expression of CXCR7 in 79 cases of PTC and its adjacent 2 cm thyroid normal tissues and 33 cases of benign thyroid diseases. Results The positive rate of CXCR7 expression in PTC tissues was 65.8% (52/79). The positive rate of CXCR7 expression was 0 (0/79) in normal tissue adjacent to thyroid cancer. The positive rate of CXCR7 expression in benign thyroid disease was 30.3. %(10/33). The positive rate of CXCR7 expression in PTC cancer tissue was significantly higher than that in benign thyroid disease tissue (P<0.05) and normal tissue adjacent to paratumor thyroid gland (P<0.05). The positive expression of CXCR7 was associated with PTC lymph node metastasis (P<0.05). Conclusion CXCR7 may participate in the occurrence, development and lymph node metastasis of PTC.